Novo, Eli Lilly slash obesity drug prices in China
Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) have begun an aggressive price-cutting campaign for their blockbuster obesity treatments in China, as the two pharmaceutical giants race to capture the world's largest patient population before local generic competition arrives.





-640x358.jpg&w=3840&q=75)



-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)